Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.
paper
Cited
Public
Unavailable
- Authors
- Schlosburg, Joel E; Carlson, Brittany L A; Ramesh, Divya; Abdullah, Rehab A; Long, Jonathan Z; Cravatt, Benjamin F; Lichtman, Aron H
- Year
- 2009
- Journal
- The AAPS journal
- PMID
- 19430909
- DOI
- 10.1208/s12248-009-9110-7
- PMCID
- PMC2691470
Abstinence symptoms in cannabis-dependent individuals are believed to contribute to the maintenance of regular marijuana use. However, there are currently no medications approved by the FDA to treat cannabis-related disorders. The only treatment currently shown consistently to alleviate cannabinoid withdrawal in both animals and humans is substitution therapy using the psychoactive constituent of marijuana, Delta(9)-tetrahydrocannabinol (THC). However, new genetic and pharmacological tools are available to increase endocannabinoid levels by targeting fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the enzymes responsible for the degradation of the endogenous cannabinoid ligands anandamide and 2-arachidonoylglycerol, respectively. In the present study, we investigated whether increasing endogenous cannabinoids levels, through the use of FAAH (-/-) mice as well as the FAAH inhibitor URB597 or the MAGL inhibitor JZL184, would reduce the intensity of withdrawal signs precipitated by the CB(1) receptor antagonist rimonabant in THC-dependent mice. Strikingly, acute administration of either URB597 or JZL184 significantly attenuated rimonabant-precipitated withdrawal signs in THC-dependent mice. In contrast, FAAH (-/-) mice showed identical withdrawal responses as wild-type mice under a variety of conditions, suggesting that the absence of this enzyme across the development of dependence and during rimonabant challenge does not affect withdrawal responses. Of importance, subchronic administration of URB597 did not lead to cannabinoid dependence and neither URB597 nor JZL184 impaired rotarod motor coordination. These results support the concept of targeting endocannabinoid metabolizing enzymes as a promising treatment for cannabis withdrawal.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders. | Maddox CJ et al. | β | 2026 | β |
| Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models. | Bedillion MF et al. | β | 2026 | β |
| Assessment of Abuse Potential of Three Indazole-Carboxamide Synthetic Cannabinoids 5F-ADB, MDMB-4en-PINACA and ADB-4en-PINACA. | Qiao Y et al. | β | 2025 | β |
| High-intensity interval training exercise decreases brain CB1 receptor levels in male and female adult rats. | Tyler J et al. | β | 2025 | β |
| The Role of Fatty Acid Binding Proteins in Neuropsychiatric Diseases: A Narrative Review. | Powell A et al. | β | 2025 | β |
| Attenuation of cannabis withdrawal symptoms by Prosopis farcta extract, its luteolin and melatonin in mice: Involvement of brain-derived neurotrophic factor and dopamine. | Ghasemian-Yadegari J et al. | β | 2024 | β |
| Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action. | Alayoubi M et al. | β | 2024 | β |
| Circulating Endocannabinoids and N-Acylethanolamines in Individuals with Cannabis Use Disorder-Preliminary Findings. | Boachie N et al. | β | 2023 | β |
| Evidence from Human Studies for Utilising Cannabinoids for the Treatment of Substance-Use Disorders: A Scoping Review with a Systematic Approach. | Gharbi KA et al. | β | 2023 | β |
| Impact of Ξ<sup>9</sup>-Tetrahydrocannabinol and oxycodone co-administration on measures of antinociception, dependence, circadian activity, and reward in mice | Slivicki RA et al. | β | 2023 | β |
| Mechanisms of cannabinoid tolerance. | Piscura MK et al. | β | 2023 | β |
| The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses. | Hill MN et al. | β | 2023 | β |
| Therapeutic Effects of Combined Treatment with the AEA Hydrolysis Inhibitor PF04457845 and the Substrate Selective COX-2 Inhibitor LM4131 in the Mouse Model of Neuropathic Pain. | Wen J et al. | β | 2023 | β |
| Assessment of dependence potential and abuse liability of Ξ<sup>8</sup>-tetrahydrocannabinol in mice. | Vanegas SO et al. | β | 2022 | β |
| Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth? | RΓΈmer Thomsen K et al. | β | 2022 | β |
| Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials. | Vuilleumier C et al. | β | 2022 | β |
| Efficacy of topical cannabinoids in the management of pain: a systematic review and meta-analysis of animal studies. | Linde LD et al. | β | 2022 | β |
| Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers. | Haney M et al. | β | 2022 | β |
| The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice. | Dodu JC et al. | β | 2022 | β |
| Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings. | Kesner AJ et al. | β | 2021 | β |
| Design, synthesis and <i>inΒ vitro</i> and <i>inΒ vivo</i> biological evaluation of flurbiprofen amides as new fatty acid amide hydrolase/cyclooxygenase-2 dual inhibitory potential analgesic agents. | Deplano A et al. | β | 2021 | β |
| Gabapentin attenuates somatic signs of precipitated THC withdrawal in mice. | Eckard ML et al. | β | 2021 | β |
| PMSF Attenuates Morphine Antinociceptive Tolerance and Dependence in Mice: Its Association with the Oxidative Stress Suppression. | Asadi Akbarabadi E et al. | β | 2021 | β |
| Cannabinoids Rescue Cocaine-Induced Seizures by Restoring Brain Glycine Receptor Dysfunction. | Zou G et al. | β | 2020 | β |
| Conformational gating, dynamics and allostery in human monoacylglycerol lipase. | Tyukhtenko S et al. | β | 2020 | β |
| Druggable Targets in Endocannabinoid Signaling. | Gregus AM et al. | β | 2020 | β |
| Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder. | Martin EL et al. | β | 2020 | β |
| Neuronal nicotinic acetylcholine receptors mediate β<sup>9</sup> -THC dependence: Mouse and human studies. | Donvito G et al. | β | 2020 | β |
| Precipitated Ξ9-THC withdrawal reduces motivation for sucrose reinforcement in mice. | Eckard ML et al. | β | 2020 | β |
| Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. | Bahji A et al. | β | 2020 | β |
| The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice. | Trexler KR et al. | β | 2020 | β |
| Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro. | Slivicki RA et al. | β | 2019 | β |
| CB<sub>1</sub> positive allosteric modulation attenuates Ξ<sup>9</sup>-THC withdrawal and NSAID-induced gastric inflammation. | Trexler KR et al. | β | 2019 | β |
| Pharmacokinetic and Pharmacodynamic Characterization of Tetrahydrocannabinol-Induced Cannabinoid Dependence After Chronic Passive Cannabis Smoke Exposure in Rats. | Ravula A et al. | β | 2019 | β |
| Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. | Galaj E et al. | β | 2019 | β |
| Cannabinoids and Pain: New Insights From Old Molecules. | VuΔkoviΔ S et al. | β | 2018 | β |
| Effects of Distal Mutations on the Structure, Dynamics and Catalysis of Human Monoacylglycerol Lipase. | Tyukhtenko S et al. | β | 2018 | β |
| Monoacylglycerol lipase (MAGL) as a promising therapeutic target. | Gil-OrdΓ³Γ±ez A et al. | β | 2018 | β |
| Neuroscience of Addiction: Relevance to Prevention and Treatment. | Volkow ND et al. | β | 2018 | β |
| Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice. | Trexler KR et al. | β | 2018 | β |
| Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure. | Panlilio LV et al. | β | 2018 | β |
| Therapeutic Effect of the Substrate-Selective COX-2 Inhibitor IMMA in the Animal Model of Chronic Constriction Injury. | Jones M et al. | β | 2018 | β |
| Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. | Bedse G et al. | β | 2018 | β |
| 2-Arachidonoylglycerol endocannabinoid signaling coupled to metabotropic glutamate receptor type-5 modulates anxiety-like behavior in the rat ventromedial prefrontal cortex. | Almeida-Santos AF et al. | β | 2017 | β |
| Cannabis Withdrawal: A Review of Neurobiological Mechanisms and Sex Differences. | Schlienz NJ et al. | β | 2017 | β |
| Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. | Grabner GF et al. | β | 2017 | β |
| The cannabinoid system and pain. | Woodhams SG et al. | β | 2017 | β |
| The endocannabinoid system as a target for addiction treatment: Trials and tribulations. | Sloan ME et al. | β | 2017 | β |
| Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats. | Bruijnzeel AW et al. | β | 2016 | β |
| Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [<sup>11</sup>C]CURB. | Boileau I et al. | β | 2016 | β |
| Keep off the grass? Cannabis, cognition and addiction. | Curran HV et al. | β | 2016 | β |
| [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. | Ceccarini J et al. | β | 2015 | β |
| Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice. | Gamage TF et al. | β | 2015 | β |
| Endocannabinoid signalling in reward and addiction. | Parsons LH et al. | β | 2015 | β |
| Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. | Muldoon PP et al. | β | 2015 | β |
| Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. | Carey CE et al. | β | 2015 | β |
| The role of the endocannabinoid system in pain. | Woodhams SG et al. | β | 2015 | β |
| Endocannabinoid 2-Arachidonoylglycerol Self-Administration by Sprague-Dawley Rats and Stimulation of in vivo Dopamine Transmission in the Nucleus Accumbens Shell. | De Luca MA et al. | β | 2014 | β |
| Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice. | Morgan DJ et al. | β | 2014 | β |
| Neuroinflammation as a possible link between cannabinoids and addiction. | Rodrigues LC et al. | β | 2014 | β |
| Novel Pharmacologic Approaches to Treating Cannabis Use Disorder. | Balter RE et al. | β | 2014 | β |
| Chemical probes of endocannabinoid metabolism. | Blankman JL et al. | β | 2013 | β |
| Diuretic effects of cannabinoids. | Paronis CA et al. | β | 2013 | β |
| Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. | Ramesh D et al. | β | 2013 | β |
| Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. | Fichna J et al. | β | 2013 | β |
| Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. | Panlilio LV et al. | β | 2013 | β |
| Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. | Kinsey SG et al. | β | 2013 | β |
| Therapeutic potential of monoacylglycerol lipase inhibitors. | Mulvihill MM et al. | β | 2013 | β |
| Monoacylglycerol lipase - a target for drug development? | Fowler CJ | β | 2012 | β |
| Production and actions of the anandamide metabolite prostamide E2 in the renal medulla. | Ritter JK et al. | β | 2012 | β |
| Activity-based protein profiling of organophosphorus and thiocarbamate pesticides reveals multiple serine hydrolase targets in mouse brain. | Nomura DK et al. | β | 2011 | β |
| Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. | Ramesh D et al. | β | 2011 | β |
| delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory. | Wise LE et al. | β | 2011 | β |
| Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. | Serrano A et al. | β | 2011 | β |
| Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. | Sidhpura N et al. | β | 2011 | β |
| Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. | Sciolino NR et al. | β | 2011 | β |
| Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. | Kinsey SG et al. | β | 2011 | β |
| Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. | Kinsey SG et al. | β | 2011 | β |
| Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. | Lass A et al. | β | 2011 | β |
| Marijuana dependence: not just smoke and mirrors. | Ramesh D et al. | β | 2011 | β |
| Pharmacological treatment of cannabis dependence. | Weinstein AM et al. | β | 2011 | β |
| The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys. | Stewart JL et al. | β | 2011 | β |
| Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases. | Long JZ et al. | β | 2010 | β |
| Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. | Schlosburg JE et al. | β | 2010 | β |
| FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. | Falenski KW et al. | β | 2010 | β |
| Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. | Filbey FM et al. | β | 2010 | β |
| Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. | Long JZ et al. | β | 2009 | β |